The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Journal of the Canadian Urological Association

Volumn 5, Issue 2, 2011, Pages

  Vesprini, Danny ^a,b   Narod, Steven A ^c   Trachtenberg, John ^a,d   Crook, Juanita ^a,d   Jalali, Farid ^d   Preiner, John ^e   Sridhar, Srikala ^c,d   Bristow, Robert G ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e Southlake Regional Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953283583     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.10080     Document Type: Article

References (34)

1. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
2. Thompson D, Easton DF. title typecontributorCancer Incidence in BRCA1 mutation carriers/title. J Natl Cancer Inst 2002;94:1358-65.
3. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-7.
4. Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008;99:371-4.
5. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929-35.
6. Higgins GS, Prevo R, Lee YF, et al. A small interfering RNA screen of genes involved in DNA repair identifies tumour-specific radiosensitization by POLQ knockdown. Cancer Res 2010;70:2984-93.
7. Ernestos B, Nikolaos P, Koulis G, et al. Increased chromosomal radiosensitivity in women carrying BRCA1/ BRCA2 mutations assessed with the G2 assay. Int J Radiat Oncol Biol Phys 2010;76:1199-205.
8. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90.
9. Bristow RG, Ozcelik H, Jalali F, et al. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol 2007;83:220-30.
10. Evers B, Schut E, van der Burg E, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumours. Clin Cancer Res 2010;16:99-108.
11. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
12. Powell SN, Kachnic LA. Therapeutic exploitation of tumour cell defects in homologous recombination. Anticancer Agents Med Chem 2008;8:448-60.
13. Promkan M, Liu G, Patmasiriwat P, et al. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells. Int J Cancer 2009;125:2820-8.
14. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010;46:9-20.
15. Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCA1 function increases the antitumour activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009;8:648-53.
16. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91.
17. Treszezamsky AD, Kachnic LA, Feng Z, et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposideinduced DNA double-strand breaks via topoisomerase II. Cancer Res 2007;67:7078-81.
18. Fourquet A, Stoppa-Lyonnet D, Kirova YM, et al. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 2009;32:127-31.
19. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
20. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
21. Morimatsu M, Donoho G, Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. Cancer Res 1998;58:3441-7.
22. Nieuwenhuis B, Van Assen-Bolt AJ, Van Waarde-Verhagen MA, et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol 2002;78:285-95.
23. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-10.
24. Tutt A, Connor F, Bertwistle D, et al. Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity. Oncogene 2003;22:2926-31.
25. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
26. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833-40.
27. Gayther SA, de Foy KA, Harrington P, et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 2000;60:4513-8.
28. Ostrander EA, Udler MS. The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev 2008;17:1843-8.
29. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009;115:359-63.
30. Egawa C, Miyoshi Y, Takamura Y, et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001;95:255-9.
31. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360-9.
32. Al Rashid ST, Dellaire G, Cuddihy A, et al. Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res 2005;65:10810-21.
33. Bhogal N, Kaspler P, Jalali F, et al. Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res 2010;173:1-9.
34. Choudhury A, Zhao H, Jalali F, et al. Targeting homologous recombination using imatinib results in enhanced tumour cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009;8:203-13.